The Effect of Ranitidine on Olanzapine-Induced Weight Gain

الملخص EN

Induced weight gain is a disturbing side effect of Olanzapine that affects the quality of life in psychotic patients.

The aim of this study was to assess the efficacy of Ranitidine in attenuating or preventing Olanzapine-induced weight gain.

A parallel 2-arm clinical trial was done on 52 patients with schizophrenia, schizoaffective and schizophreniform disorders who received Olanzapine for the first time.

All these were first-episode admitted patients.

They were randomly allocated to receive either Ranitidine or placebo.

The trend of body mass index (BMI) was compared between groups over 16-week course of treatment.

Mean weight was 62.3 (SD: 9.6) kg at baseline.

Thirty-three subjects (63.5%) had positive family history of obesity.

The average BMI increment was 1.1 for Ranitidine group and 2.4 for the placebo group.

The multivariate analysis showed this effect to be independent of sex, family history of obesity, and baseline BMI value.

The longitudinal modeling after controlling for baseline values failed to show the whole trend slope to be different.

Although the slight change in trend’s slope puts forward a hypothesis that combined use of Ranitidine and Olanzapine may attenuate the weight gain long run, this needs to be retested in future larger scale long-term studies.

This trial is registered with IRCT.ir 201009112181N5.